Neurocognitive Disorders Archives

Cognitive Impairment 3 to 12 Months After COVID-19 Hospitalization

By

Ron Goldberg

May 12, 2022

Researchers assessed the frequency and severity of cognitive impairments over time and specifically 1 year after hospitalization in patients who contracted COVID-19.

Neurocognitive Disorders

Is Late-Onset Depression a Prodrome to Major Neurocognitive Disorder?

By

Jessica Nye, PhD

May 11, 2022

In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.

General Neurology

Computerized Cognitive Training May Improve HIV-Associated Neurocognitive Disorder

By

Jessica Nye, PhD

May 4, 2022

Researchers assessed whether computerized cognitive training programs were associated with improvements in overall cognitive and daily function in patients with HIV infection.

Neurocognitive Disorders

Memory Concerns Stable, but Incidence of Cognitive Decline Increased

April 19, 2022

Rates of memory concerns among older adults remained stable, but the incidence of cognitive decline more than doubled between 2009 and 2018.

Neurocognitive Disorders

Risk for Decline Up for Low-Income Seniors After ICU Stay

March 18, 2022

Community-dwelling older adults with dual eligibility for Medicare and Medicaid have an increased risk for decline in function and cognition after intensive care unit (ICU) hospitalization.

Alzheimer's Disease and Dementia

AAN Issues Review of Evidence for Aducanumab in Alzheimer Disease

March 14, 2022

Class I study shows single doses of aducanumab safe, well tolerated; class II studies show reduced amyloid deposition on brain PET at one year.

In the transition from RRMS to SPMS, inflammation that occurs early in the disease process slowly decreases over time, but a gradual worsening of symptoms occurs. The challenge for clinicians is to determine whether worsening symptoms are from the last relapse, or whether the patient has progressed to SPMS. A careful history of changes in a patient’s symptoms, neurologic examination, and MRI can help determine whether the transition has occurred. Interferon beta (Avonex, Betaseron, Extavia and Rebif), Aubagio (teriflunomide), Gilenya (fingolimod), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab) are approved by the FDA for use in relapsing forms of MS, including SPMS. Many of those who progress to SPMS continue using these medications unless they are no longer adequately controlling disease activity. In this case, patients may transition to Novantrone (mitoxantrone), the only medication approved by the FDA specifically for SPMS, as well as worsening relapsing MS.

Neurocognitive Disorders

The Link, Potential Mechanism Between Sarcopenia and Motoric Cognitive Risk Syndrome

By

Sheila Jacobs

March 11, 2022

Using an established moderated mediation model, researchers investigated the association and potential pathways between sarcopenia and motoric cognitive risk syndrome in older adults.

Alzheimer's Disease and Dementia

Persistent Loneliness May Increase 10-Year Risk for Dementia

By

Colby Stong

March 2, 2022

Researchers sought to determine the association of loneliness with 10-year all-cause dementia risk and the cross-sectional association of loneliness with early markers of Alzheimer disease and related dementia vulnerability.

Scientist-Conducting-Experiment-THC-Cannabis

Neurocognitive Disorders

Novel Brain Imaging System Quantifies THC-Related Impairment in Cannabis Users

By

Jessica Nye, PhD

March 1, 2022

Researchers sought to evaluate the capability of a portable imaging system to effectively quantify THC impairment in cannabis users.

Alzheimer's Disease and Dementia

Defining the Behavioral Variant of Alzheimer Disease

By

Mary Stroka

March 1, 2022

The authors searched PubMed/MEDLINE and Web of Science databases for studies of clinically diagnosed AD cases with frontal or behavioral presentations or bvFTD cases with neuropathological evidence of AD.